Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac

Vaccine

Volumn 30, Issue 34, 2012, Pages 5059-5062

  Caron, François ^a,b   Delbos, Valérie ^a,b   Houivet, Estelle ^c   Deghmane, Ala Eddine ^d   Leroy, Jean Philippe ^a   Hong, Eva ^d   Bénichou, Jacques ^c,e   Taha, Muhamed Kheir ^d  

^a Service des Maladies Infectieuses et Tropicales   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITÉ DE ROUEN   (France)

Author keywords

Immune response; Neisseria meningitidis; Outer membrane vesicle vaccine

Indexed keywords

COMPLEMENT; MENINGOCOCCUS VACCINE;

ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MOLECULAR EVOLUTION; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; TREATMENT DURATION; VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD, PRESCHOOL; COMPLEMENT SYSTEM PROTEINS; FRANCE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; SERUM BACTERICIDAL TEST;

EID: 84863784907     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.051     Document Type: Article

References (12)

1. ECDC Surveillance of invasive bacterial diseases in Europe 2008-2009 2011, http://www.ecdc.europa.eu/en/publications/Publications/1107_SUR_IBD_2008-09.pdf.
2. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969, 129:1327-1348.
3. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338:1093-1096.
4. Caron F., Parent du Châtelet I., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11:455-463.
5. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA 1999, 281:1520-1527.
6. Frasch C.E., Borrow R., Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B112-B116.
7. Santos G.F., Deck R.R., Donnelly J., Blackwelder W., Granoff D.M. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001, 8:616-623.
8. Trotter C., Borrow R., Andrews N., Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003, 21:1094-1098.
9. Feiring B., Fuglesang J., Oster P., Naess L.M., Helland O.S., Tilman S., et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 2006, 13:790-796.
10. Trotter C., Findlow J., Balmer P., Holland A., Barchha R., Hamer N., et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 2007, 14:863-868.
11. Holst J., Feiring B., Fuglesang J.E., Hoiby E.A., Nokleby H., Aaberge I.S., et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21:734-737.
12. Delbos V., Lemee L., Bénichou J., Berthelot G., Taha M.K., Caron F. Impact of antibiotic exposure and outer membrane vesicle vaccination on meningococcal carriage during a meningococcal B outbreak. Interscience Conference on Antimicrobial Agents and Chemotherapy 2011.